

AMENDMENTS

In the Claims:

1. (Currently Amended) An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH₂ (447).
2. (Currently Amended) An antibody subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which both C-terminals of the heavy chain are Pro-NH₂ (447).
3. (Currently Amended) The antibody subtype according to claim 1 or 2 wherein the heavy chain of the native humanized PM-1 antibody corresponding to the subtype according to claim 1 or 2 has a heavy chain that corresponds to amino acids 1-448 of an amino acid sequence set forth in SEQ ID NO: 1, and a heavy chain of the subtype antibody having the C-terminal Pro-NH₂ corresponds to amino acids 1-447 of SEQ ID NO:1.
4. (Original) The antibody subtype according to claim 3 wherein glutamine (Gln) at the heavy chain N-terminal is pyroglutamic acid (pGlu).
5. (Currently Amended) The antibody subtype according to claim ~~any one of claims 1, to 4~~ wherein the light chain of the above humanized PM-1 antibody subtype has an amino acid sequence set forth in SEQ ID NO: 2.
6. (Currently Amended) A pharmaceutical composition comprising ~~either the antibody subtype (1) of claim 1 or the subtype (2) described in any one of claims 1-5, or both of the subtypes (1) and (2).~~ the antibody subtype (1) of claim 1 or the subtype (2) described in any one of claims 1-5, or both of the subtypes (1) and (2).
7. (New) The antibody subtype according to claim 2, wherein the light chain of the above humanized PM-1 antibody subtype has an amino acid sequence set forth in SEQ ID NO: 2.
8. (New) A pharmaceutical composition comprising the antibody subtype (2) of claim 2.

9. (New) A pharmaceutical composition comprising:

an antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH₂; and

an antibody subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which both C-terminals of the heavy chain are Pro-NH₂.